Home › Compound Library › Glecaprevir

Glecaprevir

Antiviralprescriptionoral · inferred

Pan-genotypic HCV NS3/4A protease inhibitor; component of Mavyret (glecaprevir/pibrentasvir). 8-12 week curative course. Significant OATP1B1 and P-gp substrate; CYP3A-mediated metabolism.

Projected serum levels — 300 mg, once daily

Glecaprevir
Glecaprevir modeled serum levels, 300 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 50 100 150 200 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 300 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 113 mg, trough ≈ 18.0 mg body load. Population-based estimate over 15 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiviral
Route modeled
Oral
Model confidence
inferred
Half-life
6 h
Common dose
300 mg
Suggested maximum
300 mg/day
Reference dose range
150–300 mg (single dose)
Suggested cadence
once daily
Validated against
300 mg oral — Cmax 1.7 mg/L at 5 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Glecaprevir CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Glecaprevir AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Glecaprevir CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Glecaprevir AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Glecaprevir CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Glecaprevir AUC by ~5.00x

  • contraindicated
    Diltiazem + Glecaprevir CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Glecaprevir AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Glecaprevir CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Glecaprevir AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Glecaprevir CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Glecaprevir AUC by ~10.00x

Serum checks 570 modeled interaction pairings for glecaprevir across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-Infected Adults Lin CW et al. · Clinical Pharmacokinetics, 2019 DOI

    Population PK analysis of glecaprevir/pibrentasvir establishing exposure-response relationships and DDI risk.

  2. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection Zeuzem S et al. · New England Journal of Medicine, 2018 DOI

    ENDURANCE-1/3 trials showed 99% SVR with 8-week glec/pib in treatment-naive non-cirrhotic patients.

2 published studies referenced in the app, each with a plain-language summary.